Regulatory Forum Opinion Piece*: Retrospective Evaluation of Doses in the 26-week Tg.rasH2 Mice Carcinogenicity Studies: Recommendation to Eliminate High Doses at Maximum Tolerated Dose (MTD) in Future Studies.
High doses in Tg.rasH2 carcinogenicity studies are usually set at the maximum tolerated dose (MTD), although this dose selection strategy has not been critically evaluated. We analyzed the body weight gains (BWGs), mortality, and tumor response in control and treated groups of 29 Tg.rasH2 studies conducted at BioReliance. Based on our analysis, it is evident that the MTD was exceeded at the high and/or mid-doses in several studies. The incidence of tumors in high doses was lower when compared to the low and mid-doses of both sexes. Thus, we recommend that the high dose in male mice should not exceed one-half of the estimated MTD (EMTD), as it is currently chosen, and the next dose should be one-fourth of the EMTD. Because females were less sensitive to decrements in BWG, the high dose in female mice should not exceed two-third of EMTD and the next dose group should be one-third of EMTD. If needed, a third dose group should be set at one-eighth EMTD in males and one-sixth EMTD in females. In addition, for compounds that do not show toxicity in the range finding studies, a limit dose should be applied for the 26-week carcinogenicity studies.
BioReliance by SAFC, Rockville, Maryland, USA madhav.paranjpe@bioreliance.com.
Madhav G
MG
Paranjpe
BioReliance by SAFC, Rockville, Maryland, USA.
Melissa D
MD
Denton
BioSTAT Consultants, Inc., Portage, Michigan, USA.
Tom J
TJ
Vidmar
BioReliance by SAFC, Rockville, Maryland, USA.
Reem H
RH
Elbekai
D000818:Animals; D015197:Carcinogenicity Tests / Q000379:methods* / Q000592:standards; D004353:Drug Evaluation, Preclinical / Q000379:methods* / Q000592:standards; D005260:Female; D008297:Male; D020714:Maximum Tolerated Dose; D051379:Mice; D008822:Mice, Transgenic; D010336:Pathology; D012189:Retrospective Studies; D014116:Toxicology
MTD; Tg.rash2; alternative models in toxicology; carcinogenesis; preclinical research and development; toxicologic pathology